These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 39225462)

  • 1. Underlying mechanisms and management strategies for regorafenib-induced toxicity in hepatocellular carcinoma.
    Cheng M; Tao X; Wang F; Shen N; Xu Z; Hu Y; Huang P; Luo P; He Q; Zhang Y; Yan F
    Expert Opin Drug Metab Toxicol; 2024 Sep; 20(9):907-922. PubMed ID: 39225462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Outcomes of 2nd- and 3rd-Line Regorafenib for Advanced Hepatocellular Carcinoma.
    Naruto K; Kawaoka T; Amioka K; Ogawa Y; Chihiro K; Yoshikawa Y; Ando Y; Suehiro Y; Kosaka Y; Uchikawa S; Kodama K; Morio K; Fujino H; Murakami E; Nakahara T; Yamauchi M; Tsuge M; Hiramatsu A; Fukuhara T; Takaki S; Mori N; Tsuji K; Nonaka M; Hyogo H; Aisaka Y; Masaki K; Honda Y; Kohno H; Kohno H; Moriya T; Naeshiro N; Azakami T; Imamura M; Chayama K; Aikata H
    Oncology; 2021; 99(8):491-498. PubMed ID: 34000725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regorafenib: A Review in Hepatocellular Carcinoma.
    Heo YA; Syed YY
    Drugs; 2018 Jun; 78(9):951-958. PubMed ID: 29915898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
    Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
    Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study.
    Bruix J; Tak WY; Gasbarrini A; Santoro A; Colombo M; Lim HY; Mazzaferro V; Wiest R; Reig M; Wagner A; Bolondi L
    Eur J Cancer; 2013 Nov; 49(16):3412-9. PubMed ID: 23809766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regorafenib for the treatment of unresectable hepatocellular carcinoma.
    Rimassa L; Pressiani T; Personeni N; Santoro A
    Expert Rev Anticancer Ther; 2017 Jul; 17(7):567-576. PubMed ID: 28580808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea.
    Lee MJ; Chang SW; Kim JH; Lee YS; Cho SB; Seo YS; Yim HJ; Hwang SY; Lee HW; Chang Y; Jang JY
    Invest New Drugs; 2021 Feb; 39(1):260-268. PubMed ID: 32749658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of LSD1 enhances the cytotoxic and apoptotic effects of regorafenib in hepatocellular carcinoma cells.
    Wu LW; Zhou DM; Zhang ZY; Zhang JK; Zhu HJ; Lin NM; Zhang C
    Biochem Biophys Res Commun; 2019 May; 512(4):852-858. PubMed ID: 30929918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regorafenib: a newly approved drug for advanced hepatocellular carcinoma.
    Kyrochristos ID; Ziogas DE; Roukos DH
    Future Oncol; 2017 Aug; 13(19):1665-1668. PubMed ID: 28613123
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.
    De Mattia E; Cecchin E; Guardascione M; Foltran L; Di Raimo T; Angelini F; D'Andrea M; Toffoli G
    World J Gastroenterol; 2019 Aug; 25(29):3870-3896. PubMed ID: 31413525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness of regorafenib as second-line therapy for patients with advanced hepatocellular carcinoma.
    Parikh ND; Singal AG; Hutton DW
    Cancer; 2017 Oct; 123(19):3725-3731. PubMed ID: 28662266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lenvatinib as a therapy for unresectable hepatocellular carcinoma.
    Spallanzani A; Orsi G; Andrikou K; Gelsomino F; Rimini M; Riggi L; Cascinu S
    Expert Rev Anticancer Ther; 2018 Nov; 18(11):1069-1076. PubMed ID: 30220234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical comparison of regorafenib and sorafenib efficacy for hepatocellular carcinoma using multimodality molecular imaging.
    Liu S; Du Y; Ma H; Liang Q; Zhu X; Tian J
    Cancer Lett; 2019 Jul; 453():74-83. PubMed ID: 30928380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regorafenib: a promising treatment for hepatocellular carcinoma.
    Cerrito L; Ponziani FR; Garcovich M; Tortora A; Annicchiarico BE; Pompili M; Siciliano M; Gasbarrini A
    Expert Opin Pharmacother; 2018 Dec; 19(17):1941-1948. PubMed ID: 30345837
    [No Abstract]   [Full Text] [Related]  

  • 15. Benefit-Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib.
    Pelosof L; Lemery S; Casak S; Jiang X; Rodriguez L; Pierre V; Bi Y; Liu J; Zirkelbach JF; Patel A; Goldberg KB; McKee AE; Keegan P; Pazdur R
    Oncologist; 2018 Apr; 23(4):496-500. PubMed ID: 29386313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial.
    Finn RS; Merle P; Granito A; Huang YH; Bodoky G; Pracht M; Yokosuka O; Rosmorduc O; Gerolami R; Caparello C; Cabrera R; Chang C; Sun W; LeBerre MA; Baumhauer A; Meinhardt G; Bruix J
    J Hepatol; 2018 Aug; 69(2):353-358. PubMed ID: 29704513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. STAT3 mediates regorafenib-induced apoptosis in hepatocellular carcinoma.
    Tai WT; Chu PY; Shiau CW; Chen YL; Li YS; Hung MH; Chen LJ; Chen PL; Su JC; Lin PY; Yu HC; Chen KF
    Clin Cancer Res; 2014 Nov; 20(22):5768-76. PubMed ID: 25248379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regorafenib, an investigational agent for the treatment of cholangiocarcinoma.
    Sahin IH; Tan E; Kim R
    Expert Opin Investig Drugs; 2021 Apr; 30(4):333-341. PubMed ID: 33378249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regorafenib in advanced hepatocellular carcinoma (HCC): considerations for treatment.
    Kim K; Jha R; Prins PA; Wang H; Chacha M; Hartley ML; He AR
    Cancer Chemother Pharmacol; 2017 Nov; 80(5):945-954. PubMed ID: 28932966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving regorafenib's organ target precision via nano-assembly to change its delivery mode abolishes chemoresistance and liver metastasis of colorectal cancer.
    Liu J; Fu D; Wang K; Yuan Y; Deng Y; Shi L; Li M; Zhou C; Lu X; Lv Q; Wang G; Wang L; Wang Z
    J Colloid Interface Sci; 2022 Feb; 607(Pt 1):229-241. PubMed ID: 34500422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.